These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 28278723)

  • 1. Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia.
    Maiti A; Cortes J; Ferrajoli A; Estrov Z; Borthakur G; Garcia-Manero G; Jabbour E; Ravandi F; O'Brien S; Kantarjian H
    Leuk Lymphoma; 2017 Sep; 58(9):1-6. PubMed ID: 28278723
    [No Abstract]   [Full Text] [Related]  

  • 2. Imatinib activity in vitro in tumor cells from patients with chronic myeloid leukemia in chronic phase and blast crisis.
    Olsson-Strömberg U; Aleskog A; Björnberg A; Höglund M; Simonsson B; Bengtsson M; Barbany G; Larsson R; Lindhagen E
    Anticancer Drugs; 2006 Jul; 17(6):631-9. PubMed ID: 16917208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia.
    O'Brien S; Talpaz M; Cortes J; Shan J; Giles FJ; Faderl S; Thomas D; Garcia-Manero G; Mallard S; Beth M; Koller C; Kornblau S; Andreeff M; Murgo A; Keating M; Kantarjian HM
    Cancer; 2002 Apr; 94(7):2024-32. PubMed ID: 11932905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omacetaxine Mepesuccinate for Chronic Myeloid Leukemia.
    Rosshandler Y; Shen AQ; Cortes J; Khoury HJ
    Expert Rev Hematol; 2016 May; 9(5):419-24. PubMed ID: 26853281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Undetectable molecular residual disease after omacetaxine and nilotinib combination therapy in an imatinib-resistant chronic myeloid leukaemia patient harbouring the BCR-ABL1 T315I gatekeeper mutation.
    Coude MM; Luycx O; Cariou ME; Maarek O; Dombret H; Cayuela JM; Rea D
    Br J Haematol; 2012 May; 157(3):407-10. PubMed ID: 22225474
    [No Abstract]   [Full Text] [Related]  

  • 6. Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib.
    Marin D; Kaeda JS; Andreasson C; Saunders SM; Bua M; Olavarria E; Goldman JM; Apperley JF
    Cancer; 2005 May; 103(9):1850-5. PubMed ID: 15786422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Standard-dose imatinib plus low-dose homoharringtonine and granulocyte colony-stimulating factor is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis who have failed prior single-agent therapy with imatinib.
    Fang B; Li N; Song Y; Han Q; Zhao RC
    Ann Hematol; 2010 Nov; 89(11):1099-105. PubMed ID: 20499235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
    Cohen MH; Johnson JR; Pazdur R
    Clin Cancer Res; 2005 Jan; 11(1):12-9. PubMed ID: 15671523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804.
    Stone RM; Donohue KA; Stock W; Hars V; Linker CA; Shea T; Deangelo DJ; Marcucci G; Bloomfield CD; Larson RA;
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):859-64. PubMed ID: 18670778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Homoharringtonine effective in CML patients.
    Hitt E
    Lancet Oncol; 2002 May; 3(5):259. PubMed ID: 12067785
    [No Abstract]   [Full Text] [Related]  

  • 11. Isolated blast crisis relapse in the central nervous system of a patient treating for a chronic myelogenous leukemia.
    Boudiaf H; Ezziane K; Rouis NO; Himrane M; Hakem S; Benchabane H; Boukhelal H; Arous R; Chikhi L
    Pan Afr Med J; 2020; 36():142. PubMed ID: 32874406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of homoharringtonine in patients with chronic myeloid leukemia who have failed or responded suboptimally to imatinib therapy.
    Li YF; Liu X; Liu DS; Din BH; Zhu JB
    Leuk Lymphoma; 2009 Nov; 50(11):1889-91. PubMed ID: 19860613
    [No Abstract]   [Full Text] [Related]  

  • 13. The plicamycin and hydroxyurea combination chemotherapy for chronic granulocytic leukemia in myeloid transformation.
    Antimi M; Masi M; Delannoy A; Ferrant A; Doyen C; Debusscher L; Delwiche F; Stryckmans P; Papa G
    Haematologica; 1990; 75(5):443-6. PubMed ID: 2151448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase.
    Quintás-Cardama A; Kantarjian H; Garcia-Manero G; O'Brien S; Faderl S; Ravandi F; Giles F; Thomas D; Wierda W; Cortes J
    Leuk Lymphoma; 2007 Feb; 48(2):283-9. PubMed ID: 17325887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pioglitazone with imatinib in CML may reduce residual disease.
    Brower V
    Lancet Oncol; 2017 Feb; 18(2):e70. PubMed ID: 28089103
    [No Abstract]   [Full Text] [Related]  

  • 16. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
    Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
    Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
    O'Brien S; Giles F; Talpaz M; Cortes J; Rios MB; Shan J; Thomas D; Andreeff M; Kornblau S; Faderl S; Garcia-Manero G; White K; Mallard S; Freireich E; Kantarjian HM
    Cancer; 2003 Sep; 98(5):888-93. PubMed ID: 12942553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Homoharringtonine combined with cytarabine to treat chronic myelogenous leukemia in myeloid blast crisis and its impact on bone marrow CD34+CD7+ cells.
    Li Y; Deng Z; Zho J; Ding B; Shi Y; Li Y
    Acta Haematol; 2014; 132(2):172-6. PubMed ID: 24603361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imatinib Intolerance Is Associated With Blastic Phase Development in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia.
    Ángeles-Velázquez JL; Hurtado-Monroy R; Vargas-Viveros P; Carrillo-Muñoz S; Candelaria-Hernández M
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S82-5. PubMed ID: 27521331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Very long survival in complete cytogenetic remission in an adolescent with lymphoid blast crisis of chronic myeloid leukemia after treatment with intensive ALL-directed chemotherapy combined with continuous imatinib.
    Maschan A; Novichkova G; Miakova N; Persiantseva M
    Pediatr Blood Cancer; 2016 Dec; 63(12):2243-2245. PubMed ID: 27434016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.